On Thursday, 13th January 2022, AstraZeneca said that, the primary analysis of the ongoing immunogenicity and safety trial has now been indicating that, the Vaxzevria, when it has been given as the third corona virus vaccine booster dose, along with the increased response of the antibody to the Omicron corona virus variant.
The research has also noted that, the corona virus booster vaccine dosage of the novel corona virus vaccine known as Vaxzevria of the company has also increased the immune response to the Delta, Alpha, Gamma and Beta variants of the corona virus, and the results had also observed that, among the individuals has previously been vaccinated with either the mRNA vaccine of AstraZeneca.
According to the reports of the new data from the ongoing trials of the AstraZeneca and Oxford University corona virus vaccine trials has also shown that, the three doses of the corona virus vaccine doses have given better protection against the Omicron covid-19 variant.
Under the agreement with the company ‘AstraZeneca’, the Vaxzevria corona virus vaccine has also manufactured and it has also supplied by the Serum Institute of India by the name of the Covishield vaccine.
Mene Pangalos, executive vice-president of the company ‘AstraZeneca’ said that, the covid-19 vaccine has now protected hundreds of the millions of the people from the novel corona virus vaccine across the world and these data has also been showing that, it has also been an important role for the purpose of playing as third dose of the booster covid-19 vaccine.
